Get notified of page updates

Search Results: Treatment + Breast Cancer + Triple Negative + Stage 1 (1 results)

New Search
PRINTER FRIENDLY PAGE 1 through 1 of 1

Treatment
Phase 1 treatment study for early-stage or metastatic TNBC

Personalized Vaccine With Immunotherapy for Early-Stage or Metastatic Triple Negative Breast Cancer

This study is testing a personalized cancer vaccine designed using proteins (called neoantigens) taken directly from a person’s tumor.

Clinicaltrials.gov identifier: NCT06324240
Additional Results on Clinicaltrials.gov Treatment + Breast Cancer + Triple Negative + Stage 1
23 results
Clinical Trial Official Title
NCT04427293 Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT07555210 Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
NCT06966700 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT05929768 Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT01042379 I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT06635980 Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
NCT06318897 Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
NCT07211178 Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT03424005 A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT07407920 Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
NCT05677802 Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
NCT05059444 ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT06324240 Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
NCT05269381 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT06797635 Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT02945579 Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
NCT05812807 Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT07016399 Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
NCT07017673 Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
NCT06220214 Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
NCT06349642 Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
NCT06637306 Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
NCT04959474 Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

Sponsored By